Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (51-60 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology and Therapy|January 18, 2020
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?Roy Fleischmann, Vipul Jairath, Eduardo Mysler, et al.
RMD Open|May 14, 2016
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritisRoy Fleischmann, Vibeke Strand, Bethanie Wilkinson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or AdalimumabRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Nature Reviews. Rheumatology|March 12, 2024
TYK2: an emerging therapeutic target in rheumatic diseaseEric Morand, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 28, 2021
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, et al.
Arthritis Care & Research|March 1, 2021
Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid ArthritisRoy Fleischmann, Jingyu Liu, Julie Zhu, et al.
Journal of Clinical Medicine|July 2, 2020
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid ArthritisYannick Degboé, Michael Schiff, Michael Weinblatt, et al.
BMC Musculoskeletal Disorders|March 11, 2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritisRoy Fleischmann, Hyman Tannenbaum, Neha P Patel, et al.
Rheumatology (Oxford, England)|April 19, 2021
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitorsRoy Fleischmann, Mark C Genovese, Karina Maslova, et al.
Clinical Rheumatology|September 1, 2005
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxibRoy Fleischmann, Eric Sheldon, José Maldonado-Cocco, et al.
Pageof 19

Showing results (51-60 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology and Therapy|January 18, 2020
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?Roy Fleischmann, Vipul Jairath, Eduardo Mysler, et al.
RMD Open|May 14, 2016
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritisRoy Fleischmann, Vibeke Strand, Bethanie Wilkinson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or AdalimumabRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Nature Reviews. Rheumatology|March 12, 2024
TYK2: an emerging therapeutic target in rheumatic diseaseEric Morand, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 28, 2021
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, et al.
Arthritis Care & Research|March 1, 2021
Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid ArthritisRoy Fleischmann, Jingyu Liu, Julie Zhu, et al.
Journal of Clinical Medicine|July 2, 2020
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid ArthritisYannick Degboé, Michael Schiff, Michael Weinblatt, et al.
BMC Musculoskeletal Disorders|March 11, 2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritisRoy Fleischmann, Hyman Tannenbaum, Neha P Patel, et al.
Rheumatology (Oxford, England)|April 19, 2021
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitorsRoy Fleischmann, Mark C Genovese, Karina Maslova, et al.
Clinical Rheumatology|September 1, 2005
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxibRoy Fleischmann, Eric Sheldon, José Maldonado-Cocco, et al.
Pageof 19